CN101007026A - 一种抗癌药物组合物及其制备方法和用途 - Google Patents
一种抗癌药物组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN101007026A CN101007026A CN 200610042221 CN200610042221A CN101007026A CN 101007026 A CN101007026 A CN 101007026A CN 200610042221 CN200610042221 CN 200610042221 CN 200610042221 A CN200610042221 A CN 200610042221A CN 101007026 A CN101007026 A CN 101007026A
- Authority
- CN
- China
- Prior art keywords
- ganoderma
- injection
- poria
- parts
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims description 74
- 230000001093 anti-cancer Effects 0.000 title description 3
- 241000222336 Ganoderma Species 0.000 claims abstract description 85
- 239000003814 drug Substances 0.000 claims abstract description 71
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 claims abstract description 69
- 229920001491 Lentinan Polymers 0.000 claims abstract description 59
- 229940115286 lentinan Drugs 0.000 claims abstract description 59
- 229940079593 drug Drugs 0.000 claims abstract description 40
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 claims abstract description 38
- 229940095758 cantharidin Drugs 0.000 claims abstract description 35
- 229930008397 cantharidin Natural products 0.000 claims abstract description 35
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 230000036039 immunity Effects 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims description 93
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 79
- 238000002360 preparation method Methods 0.000 claims description 57
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 230000002708 enhancing effect Effects 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 12
- 239000000890 drug combination Substances 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 8
- WUQNOBSCYAIJIH-FIPCFZRWSA-N (3as,4r,7s,7ar)-2,3a,7a-trimethyl-4,5,6,7-tetrahydro-octahydro-1h-4,7-epoxyisoindole-1,3-dione Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)N(C)C2=O WUQNOBSCYAIJIH-FIPCFZRWSA-N 0.000 claims description 5
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 5
- UCMLAGLRLOPBAX-PRRDBKRISA-N (3as,4r,7s,7ar)-3a,7a-dimethyl-2-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-4,5,6,7-tetrahydro-octahydro-1h-4,7-epoxyisoindole-1,3-dione Chemical compound C1=C(OC(F)(F)F)C=C2SC(N3C(=O)[C@]4(C)[C@H]5CC[C@H](O5)[C@@]4(C3=O)C)=NC2=C1 UCMLAGLRLOPBAX-PRRDBKRISA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 65
- 230000000694 effects Effects 0.000 abstract description 26
- 201000011510 cancer Diseases 0.000 abstract description 13
- 208000014018 liver neoplasm Diseases 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 208000006454 hepatitis Diseases 0.000 abstract description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 2
- 206010025323 Lymphomas Diseases 0.000 abstract description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract description 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 231100000283 hepatitis Toxicity 0.000 abstract description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 238000009096 combination chemotherapy Methods 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 201000004637 gastric cardia carcinoma Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000007924 injection Substances 0.000 description 132
- 238000002347 injection Methods 0.000 description 132
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 65
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
- 241000699670 Mus sp. Species 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 36
- 238000012360 testing method Methods 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 230000002401 inhibitory effect Effects 0.000 description 27
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 22
- 229960004397 cyclophosphamide Drugs 0.000 description 22
- 239000000126 substance Substances 0.000 description 20
- 239000008215 water for injection Substances 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 229920001214 Polysorbate 60 Polymers 0.000 description 17
- 238000002512 chemotherapy Methods 0.000 description 16
- 239000008187 granular material Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 13
- 235000001727 glucose Nutrition 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 239000008107 starch Substances 0.000 description 13
- 235000019698 starch Nutrition 0.000 description 13
- 238000005303 weighing Methods 0.000 description 12
- 206010039491 Sarcoma Diseases 0.000 description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 206010003445 Ascites Diseases 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000012567 medical material Substances 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000001959 radiotherapy Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000011265 semifinished product Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000002767 hepatic artery Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005262 decarbonization Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000009287 sand filtration Methods 0.000 description 4
- 239000008227 sterile water for injection Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- -1 ucleosides Chemical class 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010019695 Hepatic neoplasm Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 235000001715 Lentinula edodes Nutrition 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000131283 Cantharis Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241001489091 Ganoderma sinense Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001481669 Meloidae Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000124079 Mylabris Species 0.000 description 1
- 241001572617 Mylabris cichorii Species 0.000 description 1
- 241001572616 Mylabris phalerata Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 229920001231 Polysaccharide peptide Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 给药剂量(mg/kg) | 瘤体重量(g) | 抑瘤率(%) |
生理盐水对照组 | - | 2.54±3.48 | - |
去甲斑蝥素组 | 2 | 1.43±3.36** | 43.70 |
灵芝组 | 800 | 1.74±3.40* | 31.50 |
香菇多糖组 | 1 | 1.72±3.17* | 32.28 |
茯苓组 | 2000 | 1.79±3.25* | 29.53 |
BL注射液低剂量组 | 30 | 1.26±2.69**bcde | 50.39bcde |
BL注射液中剂量组 | 60 | 1.15±2.51***abcd | 54.72abcd |
BL注射液高剂量组 | 100 | 1.03±2.62***abcd | 59.45abcd |
BX注射液低剂量组 | 2 | 1.24±2.71**abcd | 51.18abcd |
BX注射液中剂量组 | 4 | 1.11±2.64***abcd | 56.30abcd |
BX注射液高剂量组 | 8 | 0.98±2.57***abcd | 61.42abcd |
BF注射液低剂量组 | 50 | 1.25±2.63**abcd | 50.79abcd |
BF注射液中剂量组 | 100 | 1.14±2.70***abcd | 55.12abcd |
BF注射液高剂量组 | 200 | 1.05±2.58***abcd | 58.66abcd |
组别 | 给药剂量(mg/kg) | 生存天数(d) | 生命延长率(%) |
生理盐水对照组 | 2ml | 11.2±3.7 | - |
去甲斑蝥素组 | 2 | 16.1±3.5* | 43.75 |
BL注射液低剂量组 | 30 | 17.9±3.4*a | 59.82a |
BL注射液中剂量组 | 60 | 18.7±3.3**b | 66.96b |
BL注射液高剂量组 | 100 | 19.8±3.0***b | 76.79b |
BX注射液低剂量组 | 2 | 18.2±33*a | 62.50a |
BX注射液中剂量组 | 4 | 18.9±2.9**b | 68.75b |
BX注射液高剂量组 | 8 | 20.1±2.7***b | 79.46b |
BF注射液低剂量组 | 50 | 17.5±3.6*a | 56.25a |
BF注射液中剂量组 | 100 | 18.6±3.4**b | 66.07b |
BF注射液高剂量组 | 200 | 19.5±3.2***b | 74.11b |
组别 | 治疗 | 平均瘤重(g) | 抑瘤率(%) | 增效率(%) |
空白对照组 | - | 2.62±0.74 | - | - |
60Co照射组 | 0.05Gy/min | 1.54±0.65* | 41.22 | - |
60Co照射+BL注射液低剂量组 | 0.05Gy+30mg/kg | 1.21±0.62**a | 53.82a | 21.43 |
60Co照射+BL注射液中剂量组 | 0.05Gy+60mg/kg | 1.08±0.58**b | 58.78b | 29.87 |
60Co照射+BL注射液高剂量组 | 0.05Gy+100mg/kg | 0.96±0.47**b | 63.36b | 37.66 |
60Co照射+BX注射液低剂量组 | 0.05Gy+2mg/kg | 1.27±0.58**a | 51.53a | 17.53 |
60Co照射+BX注射液中剂量组 | 0.05Gy+4mg/kg | 1.12±0.47**b | 57.25b | 27.27 |
60Co照射+BX注射液高剂量组 | 0.05Gy+8mg/kg | 1.04±0.42**b | 60.31b | 32.47 |
60Co照射+BF注射液低剂量组 | 0.05Gy+50mg/kg | 1.25±0.61**a | 52.29a | 18.83 |
60Co照射+BF注射液中剂量组 | 0.05Gy+100mg/kg | 1.13±0.52**b | 56.87b | 26.62 |
60Co照射+BF注射液高剂量组 | 0.05Gy+200mg/kg | 1.06±0.43**b | 59.54b | 31.17 |
组别 | 给药剂量(mg/kg) | 平均瘤重(g) | 抑瘤率(%) | 增效率(%) | WBC(×109) | 胸腺指数 | 脾指数 |
空白对照组 | - | 2.61±1.37 | - | - | 8.63±2.26 | 27.24±6.08 | 26.31±4.92 |
注射用环磷酰胺组 | 30 | 1.56±1.28* | 40.23 | - | 3.27±1.62** | 12.31±4.73** | 13.97±2.62** |
环磷酰胺+BL注射液低剂量组 | 30+30 | 1.25±1.25**a | 52.11a | 19.87 | 6.51±1.59b | 17.48±4.49b | 17.81±3.24b |
环磷酰胺+BL注射液中剂量组 | 30+60 | 1.14±1.21***b | 56.32b | 26.92 | 7.14±1.54b | 20.49±4.78b | 19.15±3.61b |
环磷酰胺+BL注射液高剂量组 | 30+100 | 1.03±1.17***b | 60.54b | 33.97 | 7.92±1.52b | 23.15±4.49b | 21.53±4.36b |
环磷酰胺+BX注射液低剂量组 | 30+2 | 1.28±1.27**a | 50.96a | 17.95 | 6.61±1.61b | 17.35±4.37b | 17.92±3.24b |
环磷酰胺+BX注射液中剂量组 | 30+4 | 1.13±1.26***b | 56.70b | 27.56 | 7.48±1.49b | 19.91±4.61b | 19.31±3.58b |
环磷酰胺+BX注射液高剂量组 | 30+8 | 1.02±1.14***b | 60.92b | 34.62 | 7.98±1.53b | 23.15±4.97b | 21.14±4.63b |
环磷酰胺+BF注射液低剂量组 | 30+50 | 1.24±1.31**a | 52.49a | 20.51 | 6.71±1.46b | 17.42±4.35b | 17.88±3.24b |
环磷酰胺+BF注射液中剂量组 | 30+100 | 1.09±1.23***b | 58.24b | 30.13 | 7.59±1.52b | 19.96±4.75b | 19.25±3.17b |
环磷酰胺+BF注射液高剂量组 | 30+200 | 0.98±1.21***b | 62.45b | 37.18 | 8.01±1.63b | 22.96±4.43b | 21.39±4.51b |
组别 | 给药量(mg/kg) | 给药前肿瘤体积(cm3) | 给药后肿瘤体积(cm3) | 体积变化率(%) | 平均存活天数 |
生理盐水对照组 | - | 4.05 | 6.17 | +52.35 | 15.8 |
去甲斑蝥素组 | 2 | 4.11 | 2.15 | -47.69** | 18.9* |
BL注射液低剂量组 | 30 | 4.14 | 1.89 | -54.35***# | 22.4**# |
BL注射液中剂量组 | 60 | 4.02 | 1.43 | -64.43***## | 25.7***## |
BL注射液高剂量组 | 100 | 3.98 | 1.15 | -71.11***## | 28.1***## |
BX注射液低剂量组 | 2 | 4.23 | 1.95 | -53.90***# | 21.8**# |
BX注射液中剂量组 | 4 | 4.08 | 1.41 | -65.44***## | 24.6***## |
BX注射液高剂量组 | 8 | 4.16 | 1.09 | -73.80***## | 27.5***## |
BF注射液低剂量组 | 50 | 4.13 | 1.84 | -55.45***# | 22.1**# |
BF注射液中剂量组 | 100 | 3.72 | 1.32 | -64.52***## | 25.3***## |
BF注射液高剂量组 | 200 | 3.95 | 1.12 | -71.65***## | 27.9***## |
批号 | 多糖含量(%) | 得率(%) |
1 | 51.72 | 2.95 |
2 | 61.25 | 1.43 |
3 | 67.93 | 0.58 |
平均 | 60.30 | 1.65 |
批次 | 茯苓多糖含量(%) | 得率(%) |
1 | 51.63 | 9.85 |
2 | 62.79 | 8.32 |
3 | 65.06 | 8.01 |
平均 | 59.83 | 8.73 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610042221A CN100574768C (zh) | 2006-01-24 | 2006-01-24 | 一种抗癌药物组合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610042221A CN100574768C (zh) | 2006-01-24 | 2006-01-24 | 一种抗癌药物组合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101007026A true CN101007026A (zh) | 2007-08-01 |
CN100574768C CN100574768C (zh) | 2009-12-30 |
Family
ID=38695836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610042221A Expired - Fee Related CN100574768C (zh) | 2006-01-24 | 2006-01-24 | 一种抗癌药物组合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100574768C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716465A (zh) * | 2012-06-18 | 2012-10-10 | 贵州金桥药业有限公司 | 治疗肿瘤的药物组合物及其制备方法 |
CN102784162A (zh) * | 2012-08-03 | 2012-11-21 | 天津红日药业股份有限公司 | 一种食用菌类复合多糖养生保健治疗剂 |
CN103860580A (zh) * | 2014-03-27 | 2014-06-18 | 华夏先葆(北京)中药研究院有限公司 | 一种具有扶正固本、健脾和胃、增强免疫力功能的复合真菌多糖制剂 |
CN105561215A (zh) * | 2016-03-03 | 2016-05-11 | 湖北省中医院 | 一种茯灵岩健复方制剂 |
CN106248618A (zh) * | 2016-07-21 | 2016-12-21 | 中国科学院合肥物质科学研究院 | 一种基于nir光谱技术的灵芝多糖定量方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716340B (zh) * | 2012-07-06 | 2014-05-28 | 许瑞琴 | 一种用于治疗食管癌的中药 |
-
2006
- 2006-01-24 CN CN200610042221A patent/CN100574768C/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716465A (zh) * | 2012-06-18 | 2012-10-10 | 贵州金桥药业有限公司 | 治疗肿瘤的药物组合物及其制备方法 |
CN102784162A (zh) * | 2012-08-03 | 2012-11-21 | 天津红日药业股份有限公司 | 一种食用菌类复合多糖养生保健治疗剂 |
CN103860580A (zh) * | 2014-03-27 | 2014-06-18 | 华夏先葆(北京)中药研究院有限公司 | 一种具有扶正固本、健脾和胃、增强免疫力功能的复合真菌多糖制剂 |
CN103860580B (zh) * | 2014-03-27 | 2017-11-28 | 华夏先葆(北京)中药研究院有限公司 | 一种具有扶正固本、健脾和胃、增强免疫力功能的复合真菌多糖制剂 |
CN105561215A (zh) * | 2016-03-03 | 2016-05-11 | 湖北省中医院 | 一种茯灵岩健复方制剂 |
CN106248618A (zh) * | 2016-07-21 | 2016-12-21 | 中国科学院合肥物质科学研究院 | 一种基于nir光谱技术的灵芝多糖定量方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100574768C (zh) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100574768C (zh) | 一种抗癌药物组合物及其制备方法和用途 | |
CN1985864B (zh) | 一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 | |
CN104013636A (zh) | 瓦草五环三萜皂苷类化合物抗肿瘤的药物用途 | |
CN1923241B (zh) | 包括淫羊藿提取物、钩藤提取物、天麻素的药物组合物及其制备方法和应用 | |
CN1977885B (zh) | 一种抗肝炎药物组合物 | |
CN100534493C (zh) | 一种新的抗肿瘤复方药物 | |
CN1961898B (zh) | 一种复方半枝莲抗肿瘤药物组合物及其制备方法 | |
CN101623437B (zh) | 注射用生脉制剂及其制备方法 | |
CN100493522C (zh) | 一种苦参素和多糖的药物组合物 | |
CN1985873B (zh) | 甘草酸或其盐、人参和黄芪的药物组合物 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN101011543B (zh) | 一种新的抗肿瘤药物组合物 | |
CN1977886B (zh) | 一种由苦参素、灵芝和黄芪制成的药物组合物 | |
CN1954838B (zh) | 一种抗肿瘤的药物组合物 | |
CN1954839B (zh) | 由通关藤、人参和黄芪制成的药物组合物 | |
CN1961894B (zh) | 一种新的复方药物组合物及其制备方法和用途 | |
CN101073611B (zh) | 一种抗肿瘤的药物组合物 | |
CN101049336B (zh) | 一种抗癌药物组合物 | |
CN1969937B (zh) | 一种治疗肝炎的药物组合物 | |
CN1970001B (zh) | 一种苦参素、五味子和人参配伍的治疗肝炎的药物组合物 | |
CN101259180B (zh) | 一种参舌组合物及其制备方法 | |
CN1977888B (zh) | 一种由黄芩苷、灵芝和丹参制成的药物组合物 | |
CN1961895B (zh) | 一种新的抗癌药物组合物及其制备方法 | |
CN100584349C (zh) | 一种中西复方药物及其制备方法 | |
CN100482245C (zh) | 板蓝根和黄芩苷的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: XUAN ZHU SHANDONG MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: HUANG ZHENHUA Effective date: 20080516 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080516 Address after: Post encoding No. 2518 block A, Tianchen Avenue Ji'nan High-tech Development Zone in Shandong Province: 250101 Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Post encoding No. 2518 block A, Dongchen street, Ji'nan high tech Development Zone in Shandong Province: 250101 Applicant before: Huang Zhenhua |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD. Effective date: 20131008 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 226601 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131008 Address after: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee after: Haian Su Fu Technology Transfer Center Co., Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 block A Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091230 Termination date: 20170124 |
|
CF01 | Termination of patent right due to non-payment of annual fee |